Ultragenyx Pharmaceutical Announces Progression of UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta to Final Analysis

Reuters
10 Jul
Ultragenyx Pharmaceutical Announces Progression of UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta to Final Analysis

Ultragenyx Pharmaceutical Inc., along with Mereo BioPharma Group plc, has announced the progression of the UX143 (setrusumab) Phase 3 Orbit study for treating osteogenesis imperfecta in pediatric and young adult patients. This randomized, placebo-controlled study is moving toward a final analysis, expected around the end of the year. The Data Monitoring Committee has confirmed that UX143 has an acceptable safety profile, allowing the study to continue as planned. The results from this study, along with the Cosmic study, are anticipated to be available by year-end. The ongoing clinical trials will conduct final analyses after patients have received therapy for at least 18 months, with statistical thresholds set at p<0.04 for Orbit and p<0.05 for Cosmic.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9491864-en) on July 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10